The completion of mitosis is governed by the dephosphorylation of cyclin-dependent kinase (Cdk) substrates and by the ubiquitination of anaphase-promoting complex (APC) substrates. The order in ...

1 provide one explanation. The KSHV cyclin directs cellular cyclin-dependent kinase 6 (CDK6) to phosphorylate cellular Bcl-2, an inhibitor of apoptosis. Phosphorylation renders Bcl-2 unstable ...

Cyclins regulate steroid receptor action in cyclin-dependent kinase (CDK)-dependent and independent manners. In addition to regulating the cell cycle, cyclin A2 (CCNA2) also mediates female sex ...

When this protein - cyclin-dependent kinase (CDK) - was suppressed, the treatment also prevented a change in the colour of their fur. This leaves the door open for scientists to help delay the ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that helps slow the progression of cancer by inhibiting two proteins — cyclin-dependent kinase 4 and 6 (CDK4/6).

Poster presentation details are below: Author: Molina et al Title: CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft ...

FDA grants Fast Track Designation for azenosertib in Cyclin E1 positive cancer. Clinical data update to follow on January 29, 2025. Zentalis Pharmaceuticals announced that the U.S. FDA has granted ...